Results 161 to 170 of about 15,932 (195)

Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial. [PDF]

J Am Heart Assoc
Zehra A, Deng Y, Swarna KS, Herrin J, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +14 more
europepmc   +1 more source

Selective sugar transport supports Proteus mirabilis fitness in the urinary tract. [PDF]

PLoS Pathog
Shea AE, Kuo S, Gupta S, Smith SN, Appaji T, Mitchell T, Mobley HLT, Pearson MM.   +7 more
europepmc   +1 more source

Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study. [PDF]

Front Endocrinol (Lausanne)
Wang Y, Li H, Zhang Z, Kong X, Li H, Qian W, Ma J.   +6 more
europepmc   +1 more source

Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study. [PDF]

BMJ Open
Kongerud IC, Midtvedt K, Solbu MD, Øvrehus MA, Eikrem Ø, Eide IA, Heldal K, Birkeland K, Åsberg A, Jenssen TG.   +9 more
europepmc   +1 more source

Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis.

Cardiorenal Med
Huang W, Guan T, Yan Z, Cui Y, Bi S, Wu M, Yuan D.   +6 more
europepmc   +1 more source

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Barbato M, Maurea F, Canale ML, Paccone A, Bisceglia I, Tedeschi A, Scherillo M, Santagata J, Oliva S, Dessalvi CC, Forte P, D'Ambrosio C, Matola TD, Parmentola R, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension. [PDF]

Front Endocrinol (Lausanne)
Li W, Li R, Li S, Li Z, Ma J, Wu F, Chen C.   +6 more
europepmc   +1 more source

Natriuretic Effect of Dapagliflozin in Cirrhosis With Ascites: A Randomized, Placebo-Controlled Crossover Trial. [PDF]

Int J Hepatol
Kongphakdee N, Piewchan S, Sanpawithayakul K, Chonprasertsuk S, Siramolpiwat S.   +4 more
europepmc   +1 more source

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk. [PDF]

Trials
Nyein PP, Haskelberg H, Martinello M, Lowe M, Goodman-Meza D, Avihingsanon A, Kelleher AD, Rodgers A, Schutte AE, Nnakelu EC, Byakwaga H, Trevillyan J, Losso M, Kumarasamy N, Azwa RISR, Kaplan R, Clifton B, Arnott C, Dharan NJ, Petoumenos K, Matthews GV.   +20 more
europepmc   +1 more source